Laurence Albigès, MD, PhD, Describes Population With Advanced RCC Receiving Nivolumab Plus Ipilimumab in the CheckMate-214 Trial

Laurence Albigès, MD, PhD, speaks to the patient population included in the phase 3 CheckMate 214 trial, assessing nivolumab plus ipilimumab in patients with treatment-naïve advanced or metastatic renal cell carcinoma.

In an interview with CancerNetwork® during the 2022 Genitourinary Cancers Symposium, Laurence Albigès, MD, PhD, a medical oncologist and head of the Genitourinary Unit at Gustave Roussy in Villejuif, discussed the patient population included in the phase 3 CheckMate 214 trial (NCT02231749).

The trial, which assessed the use of nivolumab (Opdivo) plus ipilimumab (Yervoy) in patients with treatment-naïve advanced or metastatic renal cell carcinoma (RCC), enrolled patients with International Metastatic RCC Database Consortium (IMDC) intermediate- and poor-risk disease with at least 1 poor prognostic feature, according to Albigès.

Transcript:

The CheckMate 214 trial looked at patients with RCC who had metastatic disease that required first-line treatment. These patients could have any disease progression, either locally or at a metastatic level, and were not eligible for surgery but required systemic treatment. What is important in this trial is that the focus for the analysis is on the IMDC intermediate- and poor-[risk] patient population. These are patients who had at least 1 poor prognostic feature among 6 criteria that compose the IMDC classification. Overall, the [intent-to-treat] population in this trial also enrolled patients with [favorable]-risk disease. Nevertheless, the primary end point analysis was in the intermediate- or poor-risk population, which broadly accounted for 80% of our patient population.

Reference

Tannir NM, Signoretti S, Choueiri TK, et al. Efficacy and safety of nivolumab plus ipilimumab (N+I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up. J Clin Oncol. 2022;40(suppl 6):352. doi:10.1200/JCO.2022.40.6_suppl.352

Related Videos
Experts on RCC
Experts on RCC
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Experts on RCC
Experts on RCC
Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.
Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.
Lenvatinib plus pembrolizumab appears to be the best option for patients with refractory metastatic renal cell carcinoma who are progressing on immunotherapy combinations or are lenvatinib naïve.
Ipilimumab monotherapy does not appear effective in driving complete responses in refractory renal cell carcinoma despite yielding some progression-free survival intervals, according to an expert from the University of Texas Southwestern Medical Center.
An expert from the University of Texas Southwestern Medical Center discusses several phase 3 clinical trials supporting the use of various single-agent and combination immunotherapy regimens for advanced kidney cancer.
Related Content